Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Significant Drop in Short Interest

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) was the target of a large decline in short interest in January. As of January 15th, there was short interest totaling 13,222 shares, a decline of 26.7% from the December 31st total of 18,047 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average trading volume of 59,945 shares, the days-to-cover ratio is presently 0.2 days. Based on an average trading volume of 59,945 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.2% of the shares of the stock are short sold.

Chemomab Therapeutics Trading Up 7.7%

Chemomab Therapeutics stock traded up $0.12 during mid-day trading on Monday, hitting $1.67. The stock had a trading volume of 47,079 shares, compared to its average volume of 58,975. The stock has a 50-day simple moving average of $2.00 and a two-hundred day simple moving average of $2.82. The stock has a market capitalization of $10.29 million, a PE ratio of -0.56 and a beta of 0.56. Chemomab Therapeutics has a 12 month low of $1.53 and a 12 month high of $8.76.

Analyst Ratings Changes

Several equities analysts have issued reports on CMMB shares. Wall Street Zen upgraded Chemomab Therapeutics to a “hold” rating in a research report on Saturday, October 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Chemomab Therapeutics in a report on Monday, December 29th. Finally, Zacks Research downgraded shares of Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $26.50.

Hedge Funds Weigh In On Chemomab Therapeutics

A hedge fund recently bought a new stake in Chemomab Therapeutics stock. Kestra Private Wealth Services LLC acquired a new stake in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 51,710 shares of the company’s stock, valued at approximately $85,000. Kestra Private Wealth Services LLC owned approximately 0.84% of Chemomab Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.